(19)
(11) EP 4 253 550 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
14.02.2024 Bulletin 2024/07

(43) Date of publication:
04.10.2023 Bulletin 2023/40

(21) Application number: 22166327.1

(22) Date of filing: 01.04.2022
(51) International Patent Classification (IPC): 
C12N 15/86(2006.01)
C12N 15/11(2006.01)
 A61P 35/00(2006.01)
A61K 38/46(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/86; A61P 35/00; C12N 2310/20; C12N 15/1135; C12N 2320/12; C12N 2330/31; C12N 2330/51; C12N 15/90; A61K 38/00
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: GenCC GmbH & Co. KG
69124 Heidelberg (DE)

(72) Inventors:
  • WILKENS, Bodo, Dr.
    64285 Darmstadt (DE)
  • PATNAIK, Sarita, Dr.
    69124 Heidelberg (DE)
  • HESHMATPOUR, Najmeh, Dr.
    68723 Oftersheim (DE)
  • MACARRÓN PALACIOS, Arturo, Dr.
    64560 Riedstadt (DE)

(74) Representative: Flügge, Katharina 
Meissner Bolte Patentanwälte Rechtsanwälte Partnerschaft mbB Alter Wall 32
20457 Hamburg
20457 Hamburg (DE)

   


(54) METHOD FOR THE MANUFACTURE OF A VIRAL SYSTEM, A VECTOR SYSTEM OR ANY TRANSPORT SYSTEM FOR CANCER-SPECIFIC CRISPR COMPLEXES


(57) The present invention relates to a method for the manufacture of a viral, a vector or any transport system comprising the steps a) isolation of a class of cells from one or more sample(s) obtained from a subject; b) identifying a nucleic acid sequence that is specific for a subgroup of the class of cells; c) design of guide RNA(s) and/or DNA and/or protein directed against the nucleic acid sequence, and d) cloning of one or more sequence(s) encoding the guide RNA(s) and a Cas endonuclease into a viral system or a vector system, preferably into a viral vector, or including the guide RNA(s) and a Cas endonuclease into a viral, a vector or any transport system; and a composition comprising a viral, a vector or any transport system manufactured according to this method and its use in the treatment of cancer.